Henrik Stenqvist is joining Sobi™ as new Chief Financial Officer

Swedish Orphan Biovitrum AB (publ) (Sobi™) today announces that Henrik Stenqvist will be appointed Chief Financial Officer (CFO) and will join Sobi in late spring. Henrik will be a member of Sobi’s Executive Committee.

Henrik Stenqvist has comprehensive experience from the pharmaceutical industry with 25 years in finance and management positions. He joins Sobi from a position as CFO of Recipharm. Prior to that, Henrik Stenqvist served as the CFO of the Meda Group, where he played an instrumental role in the transformation of Meda from a small Nordic player to a leading international specialty pharma, executing numerous acquisitions as well as the integration of these.

Henrik Stenqvist holds a degree in Finance and Business Administration from the University of Linköping, Sweden.

“It is a pleasure to welcome Henrik to Sobi. His experience from the pharmaceutical industry and specifically from acquisitions and deal making in specialty pharma will be of immense value for Sobi on our journey to become a global leader in rare diseases and specialty care”, says Guido Oelkers, CEO and President of Sobi.

“I am very happy to be joining Sobi and I believe that I, through my experience, can contribute to realising Sobi’s growth strategy”, says Henrik Stenqvist.

Sobi’s current CFO, Mats-Olof Wallin, will support the transition process and will retire by year-end 2018. Mats-Olof Wallin has been an important contributor in the management of Sobi and for the Group to become a company with healthy top-line and earnings growth.

-----



About Sobi™

Sobi™ is an international speciality healthcare company dedicated to rare diseases. Our vision is to be recognised as a global leader in providing access to innovative treatments that make a significant difference for individuals with rare diseases.

The product portfolio is primarily focused on treatments in Haemophilia and Specialty Care. Partnering in the development and commercialisation of products in specialty care is a key element of our strategy. Sobi has pioneered in biotechnology with world-class

capabilities in protein biochemistry and biologics manufacturing. In 2017, Sobi had total revenues of SEK 6.5 billion and approximately 850 employees. The share (STO:SOBI) is listed on Nasdaq Stockholm. More information is available at www.sobi.com.

For more information please contact 

Media relations Investor relations
Linda Holmström, Senior Communications Manager Jörgen Winroth, Vice President, Head of Investor Relations
+46 70 873 40 95 +1 347 224 0819, +1 212 579 0506
linda.holmstrom@sobi.com  jorgen.winroth@sobi.com 

This information is information that Swedish Orphan Biovitrum AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of Linda Holmström, Senior Communications Manager, at 08:05 CET on 26 February 2018. 

Swedish Orphan Biovitrum AB
Postal address SE-112 76 Stockholm, Sweden
Phone: 46 8 697 20 00     www.sobi.com

Tags:

Subscribe

Documents & Links

Quotes

It is a pleasure to welcome Henrik to Sobi. His experience from the pharmaceutical industry and specifically from acquisitions and deal making in specialty pharma will be of immense value for Sobi on our journey to become a global leader in rare diseases and specialty care
Guido Oelkers, CEO